Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Presenters

Xiaolong Jiao

Citation

Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239

Authors

X. Jiao1, A. Lokker2, J. Snider2, E. Castellanos3, S. Nanda4, V. Fisher5, J. Zong4, K. Keating6, M. Fellous7

Author affiliations

  • 1 Biostatistics, Bayer HealthCare Pharmaceuticals, Inc., NJ07981 - Whippany/US
  • 2 Research Oncology, Flatiron Health, Inc., New York/US
  • 3 Research Oncology, Flatiron Health, Inc., 10013 - New York/US
  • 4 Biostatistics, Bayer HealthCare Pharmaceuticals, Inc., Whippany/US
  • 5 Biostatistics, Foundation Medicine, Inc., Cambridge/US
  • 6 Heor, Bayer HealthCare Pharmaceuticals, Inc., Whippany/US
  • 7 Global Medical Affairs, Bayer HealthCare Pharmaceuticals, Inc., Whippany/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5366

Background

Larotrectinib is the first therapy approved in the U.S. for locally advanced or metastatic solid tumors with neurotropic tyrosine receptor kinase (NTRK) gene fusions. NTRK gene fusions have been documented with variable frequency across numerous tumor types; limited data exist regarding the relationship of NTRK gene fusions with other targetable biomarkers. This study evaluated the co-occurrence of NTRK gene fusions with other therapy molecular markers in cancer patients.

Methods

This retrospective study included cancer patients from a de-identified Flatiron Health-Foundation Medicine Clinico-Genomic Database (CGDB) who had next-generation sequencing (NGS) between Jan 2011 and July 2018. The co-occurrence frequencies of NTRK gene fusions with the following markers was determined using NGS assays including FoundationOne and FoundationOne Heme: tumor mutation burden (TMB), microsatellite instability (MSI), ALK, BRAF, ERBB2, EGFR, ROS1, and KRAS.

Results

An evaluable sample of 15,971 of 33,398 patients in the CGDB had one of 18 histologies where at least one NTRK fusion patient was identified. NTRK gene fusions were identified in 29 patients: 55% (16/29) were female; 69% (20/29) were Caucasians. The median age was 60 years (Q1-Q3: 49.0-65.0). Fifteen different fusion partners were identified; the most frequent were ETV6-NTRK3 (n = 8), TPM3-NTRK1 (n = 6), and TPR-NTRK1 (n = 3). Co-occurring genomic alterations are shown in the table.Table: 102P

Co-occurring biomarkers*Patients with NTRK gene fusions (N = 29), % (n)
TMB High (>20 mut/mB) TMB Medium (<20, >5 mut/mB)20.7 (6/29) 10.3 (3/29)
MSI (high)17.6 (3/17)**
ALK rearrangement0.0 (0/29)
BRAF alteration3.5 (1/29)
ERBB2 amplification0.0 (0/29)
EGFR alteration3.5 (1/29)
ROS1 alteration0.0 (0/29)
KRAS alteration10.3 (3/29)
*

Variants of “known” or “likely” functional status were included

**

MSI status missing for 12 patients

Conclusions

The study confirmed the rarity of NTRK gene fusions in cancer patients. Co-occurrence of the biomarkers ALK, BRAF, ERBB2, EGFR, ROS1, or KRAS was uncommon. These results highlight the importance of identifying patients with NTRK gene fusion-driven cancers, through molecular testing, who will benefit from the use of selective TRK kinase inhibitors across different solid tumors.

Clinical trial identification

Editorial acknowledgement

Michael Sheldon, PhD, of Scion, London, UK, funded by Bayer.

Legal entity responsible for the study

Bayer.

Funding

Bayer.

Disclosure

X. Jiao: Full / Part-time employment: Bayer. A. Lokker: Full / Part-time employment: Flatiron Health; Shareholder / Stockholder / Stock options: CVS Health, Roche, Medtronic, Sangamo Therapeutics. J. Snider: Full / Part-time employment: Flatiron Health; Shareholder / Stockholder / Stock options: Roche. E. Castellanos: Full / Part-time employment: Flatiron Health. S. Nanda: Full / Part-time employment: Bayer. V. Fisher: Full / Part-time employment: Foundation Medicine. J. Zong: Full / Part-time employment: Bayer. K. Keating: Full / Part-time employment: Bayer. M. Fellous: Full / Part-time employment: Bayer.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.